New Hep C Treatment Being Tested

Article

REHOVOT, Israel - U.S. health officials estimate that more Americans will die during this decade of hepatitis C (HCV) infection than AIDS.

Officials at XTL Biopharmaceuticals Ltd. are trying to make a difference in these statistics. After successfully passing Phase IA clinical trails earlier this year with their drug XTL-002, researchers have announced the commencement of a Phase IB clinic study. The drug is a fully human, high-affinity monoclonal antibody that has reduced the viral levels of HCV virus.

The World Health Organization (WHO) estimates some 170 million people worldwide suffer from chronic HCV. There are 4 million carriers of the virus in the United States alone.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.
 Futuristic UV Sanitizer with Sleek Design on a white background.  (Adobe Stock 1375983522 by Napa)
40th Anniversary of Metrex  (Image courtesy of Metrex)